[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335761-105":59,"doc-detail-335761-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","accelerating-car-t-cell-therapies-with-small-molecule-inhibitors","Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors","","Chimeric antigen receptor T-cell (CAR-T) therapies have improved survival in patients with B-cell malignancies, yet benefits are constrained in acute myeloid leukemia and solid tumors. Limited efficacy is driven by antigen downregulation or loss, restricted access to target cells, insufficient CAR-T persistence, and an immunosuppressive tumor microenvironment. The review also addresses manufacturing difficulties and frequent toxicities, including cytokine release syndrome and ICANS. It highlights small-molecule inhibitors—many already approved clinically—as tools to support CAR-T manufacturing, strengthen anti-tumor activity, and reduce side effects, with promising pre-clinical and emerging clinical evidence for combination strategies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/accelerating-car-t-cell-therapies-with-small-molecule-inhibitors/335761/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/accelerating-car-t-cell-therapies-with-small-molecule-inhibitors/335761.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is CAR-T therapy less effective in other hematological cancers and solid tumors?","Question",{"text":113,"@type":114},"Efficacy can be limited by antigen downregulation or loss on cancer cells, restricted accessibility to target cells, and poor CAR-T persistence caused by the highly immunosuppressive tumor microenvironment.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What toxicities are commonly associated with CAR-T therapy?",{"text":118,"@type":114},"CAR-T therapy can cause cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).",{"name":120,"@type":111,"acceptedAnswer":121},"How can small-molecule inhibitors be used in CAR-T treatment?",{"text":122,"@type":114},"They can be administered as pre-medication before leukapheresis to enhance T-cell fitness, during manufacturing to maintain a memory-like phenotype and reduce exhaustion, and after infusion to prevent exhaustion, increase activity, or sensitize tumors by modulating the vasculature, tumor microenvironment, or target expression.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},335761,1790174546,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","BioDrugs (2025) 39:33–51  \n[https://doi.org/10.1007/s40259-024-00688-9](https://doi.org/10.1007/s40259-024-00688-9)  \nAccelerating CAR‑T Cell Therapies with Small‑Molecule Inhibitors  \nKatrin Mestermann 1,2 · Andoni Garitano‑Trojaola 1 · Michael Hudecek1,2  \nAccepted: 24 October 2024 / Published online: 26 November 2024 © The Author(s) 2024  \nAbstract  \nChimeric antigen receptor T-cell therapies have markedly improved the survival rates of patients with B-cell malignancies. However, their efficacy in other hematological cancers, such as acute myeloid leukemia, and in solid tumors has been limited. Key obstacles include the downregulation or loss of antigen expression on cancer cells, restricted accessibility to target cells, and the poor persistence of these “living drugs” because of the highly immunosuppressive tumor microenvironment. Additionally, manufacturing these immunotherapies presents significant challenges, and patients frequently experience side effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This review emphasizes the potential of small-molecule inhibitors, many of which are already approved for clinical use, to facilitate chimeric antigen receptor T-cell manufacturing, enhance their anti-tumor efficacy, and mitigate their side effects. Although substantial work remains, the robust pre-clinical data and the growing clinical interest suggest significant promise for using cancer signaling pathway inhibitors to enhance and refine chimeric antigen receptor T-cell therapy for both hematological and solid tumors. Exploring these combination strategies could lead to more effective therapies, offering new hope for patients with resistant forms of cancer.  \n* Katrin Mestermann [Mestermann_K@ukw.de](Mestermann_K@ukw.de)  \n1 Medizinische Klinik und Poliklinik II, Lehrstuhl für zelluläre Immuntherapie, Universitätsklinikum Würzburg, Haus E4-/ Raum 4.06, Versbacher Straße 5, 97078 Würzburg, Germany  \n2 Fraunhofer-Institut für Zelltherapie und Immunologie, Außenstelle Zelluläre Immuntherapie, Würzburg, Germany  \n1 Introduction  \nChimeric antigen receptor T-cell (CAR-T) therapy has achieved unprecedented success in treating refractory B-cell malignancies with CD19 and B-cell maturation antigen (BCMA) targeting CAR T cells [1 , 2] . However, increasing experience with these biological agents has revealed that remission is brief in a substantial number of patients because of poor CAR T-cell persistence, an immunosuppressive tumor microenvironment (TME), or cancer cell resistance [3, 4] . Additionally, CAR-T therapy can be associated with toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) [5] . Recent advances have shown that combining CAR T cells with targeted anti-cancer therapies, such as small-molecule inhibitors, can be highly effective. These combinations have demonstrated promising results in both pre-clinical and clinical studies  \n[6] . Small-molecule inhibitors can be included at different steps of CAR-T immunotherapy: (I) as a pre-medication of patients before leukapheresis to boost overall T-cell fitness;  \n(II) during manufacturing to maintain a memory-like phenotype and reduce manufacturing-associated exhaustion; and (III) after a CAR-T infusion to prevent exhaustion, increase activity, or sensitize the tumor to CAR-mediated  \nkilling by modulation of the tumor vasculature, TME, or target expression on the tumor cell surface (Fig. 1) . However, most of the clinical data on combining smallmolecule inhibitors with CAR T cells are still in the early phases. This review provides an overview of the families of small-molecule inhibitors that enhance the anti-tumor efficacy or safety of CAR T cells in both hematological and solid tumors.  \n2 Small‑Molecule Inhibitors Facilitate Manufacturing and Enhance the Anti‑Tumor Efficacy of CART Cells While Reducing Their Side Effects  \n2.1 Immunomodulatory Drugs  \nLe","cbCainSvsUi8Z1iA","https://ap.wps.com/l/cbCainSvsUi8Z1iA","pdf",1656661,"English","# Abstract\n# Introduction\n# Small-Molecule Inhibitors Facilitate Manufacturing and Enhance the Anti-Tumor Efficacy of CAR-T Cells While Reducing Their Side Effects\n## Immunomodulatory Drugs","[{\"question\":\"Why is CAR-T therapy less effective in other hematological cancers and solid tumors?\",\"answer\":\"Efficacy can be limited by antigen downregulation or loss on cancer cells, restricted accessibility to target cells, and poor CAR-T persistence caused by the highly immunosuppressive tumor microenvironment.\"},{\"question\":\"What toxicities are commonly associated with CAR-T therapy?\",\"answer\":\"CAR-T therapy can cause cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).\"},{\"question\":\"How can small-molecule inhibitors be used in CAR-T treatment?\",\"answer\":\"They can be administered as pre-medication before leukapheresis to enhance T-cell fitness, during manufacturing to maintain a memory-like phenotype and reduce exhaustion, and after infusion to prevent exhaustion, increase activity, or sensitize tumors by modulating the vasculature, tumor microenvironment, or target expression.\"}]","Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors | PDF",1790012231,48]